By 2019, Johnson & Johnson Will Apply For Registering Of More Than 10 New Drugs
The company Johnson & Johnson plans to apply for registration of more than 10 new drugs by 2019. Annual sales of each of them in the future may exceed $ 1 billion.
In particular, this year Johnson & Johnson intends to send the package of documents in regards of daratumumab designed for the treatment of blood cancer to the regulatory authorities for approval. Experts predict that the sales of daratumumaba only by 2019 will reach 1.3 billion dollars.
In the next few years sirukumab developed for the treatment of rheumatoid arthritis will also go to the control agencies as well as guselkumab that is passing clinical trials as a drug against psoriasis.
See also:
- A New Drug For The Treatment Of Obesity Entered The U.S. Market
- Johnson & Johnson Has Signed An Agreement That Implies The Development Of A Vaccine For Alzheimer's Disease
- A Drug For The Treatment Of Hypoparathyroidism Was Registered In The U.S
